One such agent, lasofoxifene, in the ELAINE (NCT03781063) study, showed encouraging antitumor activity versus fulvestrant among women with locally advanced or metastatic ER+/HER2− BC expressing ERα mutants (median PFS: 5.6 vs. 3.7 months) [120]. The gene discussed is ESR1; the disease is breast cancer.